Issue link: http://osercommunicationsgroup.uberflip.com/i/960903
AN INDEPENDENT PUBLICATION NOT AFFILIATED WITH NACDS Kimberly Oser Publisher Jules Denton-Card Senior Associate Publisher Lorrie Baumann Editorial Director Jeanie Catron • JoEllen Lowry • Karrie Welborn Associate Editors Yasmine Brown Art Director Jonathan Schieffer Graphic Designer Caitlyn McGrath • Susan Stein Customer Service Managers Jay Watson • Hannah Stefanovich • Margaret Oser Show Logistics & Distribution Marcos Morhaim Senior Account Manager Andrea Hartnett • Anthony Socci Account Managers Tara Neal Director of Operations Enrico Cecchi European Sales Chain Drugstore Daily is published by Oser Communications Group ©2018 All rights reserved. Executive and editorial offices at: 1877 N. Kolb Road, Tucson, AZ 85715 520.721.1300/Fax: 520.721.6300 European offices located at Lungarno Benvenuto Cellini, 11, 50125 Florence, Italy www.osercommunicationsgroup.com Lee M. Oser Founder Chain Drugstore Daily Monday, April 23, 2018 4 David Biernbaum Is a Booming "SmartMouth!" By Tara Kane, Director, Retail Communications David Biernbaum is Founder and President at David Biernbaum & Associates LLC, Consumer Goods Marketing, National Retail Sales, Consulting and Equity Development. Since 1977, David Biernbaum and his teams have achieved remarkable success delivering brand equity for client compa- nies, retail partners and more than 200 consumer products on today's shelves – mostly health and wellness category expanders. Since January of 2016, David Biernbaum heads up business develop- ment and strategic retail sales and mar- keting for a fast accelerating SmartMouth brand of oral health prod- ucts. In an otherwise relatively flat mouthwash category, SmartMouth is growing by more than 55 percent year after year since 2015. SmartMouth's products are scientific, premium priced and produce extremely high loyalty and results. Under Biernbaum's skilled brand- development lead- ership since late in 2015, SmartMouth oral rinses retail sales have more than doubled, to an estimated $33 mil- lion, with a projection to nearly $40 mil- lion or greater by year-end. Growth has been mostly organic, but there were also, and continue to be successful new SKU launches, including in 2017, SmartMouth Dry Mouth Rinse and Dry Mouth Mints, and currently in 2018, SmartMouth Premium Toothpaste and 2-Bottle Convenience Pack, already hitting the shelves. These new SKUs join a The Latest Additions to Aurobindo's Broad Line of Generic Pharmaceuticals Aurobindo is committed to a healthier life, and its extensive product portfolio attests to this mission. Its product range is diverse, spanning therapeutic cate- gories that provide the maximum benefit to patient populations. The following are some of the recent launches that Aurobindo has added to an already robust portfolio, including: Sumatriptan and Naproxen Sodium Tablets, Tenofovir Disoproxil Fumarate Tablets, Niacin ER Tablets and its upcoming launch of select products within its broad oral contracep- tive portfolio. As of March, Aurobindo is currently first to market Sumatriptan and Naproxen Sodium Tablets 85mg/500mg. This formulation is an AB-rated generic equivalent to the reference listed drug Treximet ® and has an estimated market size of $101.5 million. This drug is indi- cated for the acute treatment of migraine attacks with or without aura in adults. Additionally, Aurobindo has received approval for and launched Tenofovir Disoproxil Fumarate Tablets, 150mg, 200mg, 250mg and 300mg. With an estimated market size of $729.4 mil- lion, this product is an A B - r a t e d g e n e r i c equivalent to V I R E A D ® and is indicated for the treatment of HIV- 1 infection as well as for the treatment of chronic hepatitis B. This product is one in a multitude of anti-infective products for Aurobindo strategically supporting the President's Emergency Plan For AIDS Relief (PEPFAR). This government ini- tiative is aimed at addressing the global HIV/AIDS epidemic to help save the lives of those suffering from the disease, primarily in Africa. Continued on Page 29 Continued on Page 29